Sort
48,018 grants matching “immunotherapy”
DEVELOPING MULTI-ANTIGEN VACCINE FOR THE TREATMENT OF CHRONIC HBV
$768,496Valerian Nakaar · Carogen Corporation · R44 · FY2020 · DK
Induction of autophagy to enhance CAR-T cells in HIV cure approaches
$768,446Anjie Zhen · University Of California Los Angeles · R01 · FY2024 · AI
Developing new immunotherapies based of CD4 T cells
$768,394Nicholas Restifo · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Project 1: Perturbation of Pre-Existing Immunity to Chronic Viral Infection Through Immunotherapy
$768,384Georg Michael Lauer · Massachusetts General Hospital · U19 · FY2022 · AI
ENGINEERING RIG-I AGONISTS TO ENHANCE IMMUNOTHERAPY IN METASTATIC BREAST CANCER
$768,367Vanderbilt University · · FY2020 · Defense Health Agency
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
$768,331Otto O Yang · University Of California Los Angeles · R01 · FY2023 · AI
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
$768,331Otto O Yang · University Of California Los Angeles · R01 · FY2022 · AI
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
$768,331Otto O Yang · University Of California Los Angeles · R01 · FY2021 · AI
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
$768,331Otto O Yang · University Of California Los Angeles · R01 · FY2020 · AI
Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma
$768,221Christine Brown · Beckman Research Institute/City Of Hope · R01 · FY2020 · CA
Mechanisms controlling the persistence of infectious HIV reservoirs in children
$768,168Lisa M Frenkel · Seattle Children'S Hospital · R01 · FY2019 · HD
Spatially resolved, single cell biomarkers of B cell lymphoma
$768,055Akil Merchant · Cedars-Sinai Medical Center · R01 · FY2024 · CA
Defining Critical Sites of Vulnerability and Correlates of Protection to Kaposi Sarcoma Associated Herpesvirus to Inform Vaccine Design
$768,047Andrew McGuire · Fred Hutchinson Cancer Center · U01 · FY2025 · CA
SOUTHWEST ONCOLOGY GROUP - OPERATIONS OFFICE
$768,026University Of Michigan At Ann Arbor · U10 · FY2005 · CA
(PQB-3) Driver gene-induced inflammation in pancreatic cancer development
$767,979Elizabeth Marion Jaffee · Johns Hopkins University · R01 · FY2015 · CA
Role of Th17 in Severe and Recurrent C. difficile Infection
$767,972William A Petri · University Of Virginia · R01 · FY2020 · AI
Posttranscriptional control of gene expression
$767,965Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
FMIP COBRE Administrative Core
$767,751Richard J Lamont · University Of Louisville · P20 · FY2023 · GM
Development of Novel Immunotherapeutic Strategies for Myeloid Malignancies
$767,708Nirali Shah · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Comprehensive Interrogation of Toxicity Profiles Associated with Novel CAR T-cell Constructs
$767,708Nirali Shah · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Defining Critical Sites of Vulnerability and Correlates of Protection to Kaposi Sarcoma Associated Herpesvirus to Inform Vaccine Design
$767,691Andrew McGuire · Fred Hutchinson Cancer Center · U01 · FY2024 · CA
BALTIMORE PEDIATRIC AIDS CLINICAL TRIALS GROUP
$767,645Johns Hopkins University · U01 · FY2001 · AI
Engineered Immune Cells for T1D
$767,617Everett Meyer · Stanford University · R01 · FY2024 · DK
CONTROL AND ACTIVATION OF THE TUMOR NECROSIS FACTOR RECEPTORS
$767,592Gerhard Wagner · Harvard Medical School · R01 · FY2024 · AI
Assessing ADCC and Fc-mediated Protection against HIV
$767,578David T Evans · University Of Wisconsin-Madison · R01 · FY2022 · AI